Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis

Erik Tucker, Norah G. Verbout, Philberta Y. Leung, Sawan Hurst, Owen McCarty, David Gailani, Andras Gruber

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Severe bacterial sepsis often leads to a systemic procoagulant and proinflammatory condition that can manifest as disseminated intravascular coagulation, septic shock, and multiple organ failure. Because activation of the contact proteases factor XII (FXII), prekallikrein, and factor XI (FXI) can trigger coagulation and inflammatory responses, the contact factors have been considered potential targets for the treatment of sepsis. However, the pathogenic role of contact activation in severe infections has not been well defined. We therefore investigated whether an anticoagulant antibody (14E11) that selectively inhibits prothrombotic FXI activation by activated FXII (FXIIa) modifies the course of bowel perforation-induced peritoneal sepsis in mice. Early anticoagulation with 14E11 suppressed systemic thrombin- anti-thrombin complex formation, IL-6, and TNF-α levels, and reduced platelet consumption in the circulation and deposition in the blood vessels. Treatment with 14E11 within 12 hours after bowel perforation significantly improved survival compared with vehicle treatment, and the saturating dose did not increase tail bleeding. These data suggest that severe polymicrobial abdominal infection induces prothrombotic FXI activation, to the detriment of the host. Systemic anticoagulation by inhibiting FXI activation or FXIIa procoagulant activity during sepsis may therefore limit the development of disseminated intravascular coagulation without increasing bleeding risks.

Original languageEnglish (US)
Pages (from-to)4762-4768
Number of pages7
JournalBlood
Volume119
Issue number20
DOIs
StatePublished - May 17 2012

Fingerprint

Factor XI
Sepsis
Chemical activation
Inflammation
Coagulation
Disseminated Intravascular Coagulation
Thrombin
Factor XIIa
Prekallikrein
Hemorrhage
Factor XII
Multiple Organ Failure
Septic Shock
Coinfection
Anticoagulants
Blood Vessels
Blood vessels
Tail
Interleukin-6
Platelets

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. / Tucker, Erik; Verbout, Norah G.; Leung, Philberta Y.; Hurst, Sawan; McCarty, Owen; Gailani, David; Gruber, Andras.

In: Blood, Vol. 119, No. 20, 17.05.2012, p. 4762-4768.

Research output: Contribution to journalArticle

Tucker, Erik ; Verbout, Norah G. ; Leung, Philberta Y. ; Hurst, Sawan ; McCarty, Owen ; Gailani, David ; Gruber, Andras. / Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. In: Blood. 2012 ; Vol. 119, No. 20. pp. 4762-4768.
@article{ff6cc9d250dd4bb397de64c15391a1ff,
title = "Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis",
abstract = "Severe bacterial sepsis often leads to a systemic procoagulant and proinflammatory condition that can manifest as disseminated intravascular coagulation, septic shock, and multiple organ failure. Because activation of the contact proteases factor XII (FXII), prekallikrein, and factor XI (FXI) can trigger coagulation and inflammatory responses, the contact factors have been considered potential targets for the treatment of sepsis. However, the pathogenic role of contact activation in severe infections has not been well defined. We therefore investigated whether an anticoagulant antibody (14E11) that selectively inhibits prothrombotic FXI activation by activated FXII (FXIIa) modifies the course of bowel perforation-induced peritoneal sepsis in mice. Early anticoagulation with 14E11 suppressed systemic thrombin- anti-thrombin complex formation, IL-6, and TNF-α levels, and reduced platelet consumption in the circulation and deposition in the blood vessels. Treatment with 14E11 within 12 hours after bowel perforation significantly improved survival compared with vehicle treatment, and the saturating dose did not increase tail bleeding. These data suggest that severe polymicrobial abdominal infection induces prothrombotic FXI activation, to the detriment of the host. Systemic anticoagulation by inhibiting FXI activation or FXIIa procoagulant activity during sepsis may therefore limit the development of disseminated intravascular coagulation without increasing bleeding risks.",
author = "Erik Tucker and Verbout, {Norah G.} and Leung, {Philberta Y.} and Sawan Hurst and Owen McCarty and David Gailani and Andras Gruber",
year = "2012",
month = "5",
day = "17",
doi = "10.1182/blood-2011-10-386185",
language = "English (US)",
volume = "119",
pages = "4762--4768",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis

AU - Tucker, Erik

AU - Verbout, Norah G.

AU - Leung, Philberta Y.

AU - Hurst, Sawan

AU - McCarty, Owen

AU - Gailani, David

AU - Gruber, Andras

PY - 2012/5/17

Y1 - 2012/5/17

N2 - Severe bacterial sepsis often leads to a systemic procoagulant and proinflammatory condition that can manifest as disseminated intravascular coagulation, septic shock, and multiple organ failure. Because activation of the contact proteases factor XII (FXII), prekallikrein, and factor XI (FXI) can trigger coagulation and inflammatory responses, the contact factors have been considered potential targets for the treatment of sepsis. However, the pathogenic role of contact activation in severe infections has not been well defined. We therefore investigated whether an anticoagulant antibody (14E11) that selectively inhibits prothrombotic FXI activation by activated FXII (FXIIa) modifies the course of bowel perforation-induced peritoneal sepsis in mice. Early anticoagulation with 14E11 suppressed systemic thrombin- anti-thrombin complex formation, IL-6, and TNF-α levels, and reduced platelet consumption in the circulation and deposition in the blood vessels. Treatment with 14E11 within 12 hours after bowel perforation significantly improved survival compared with vehicle treatment, and the saturating dose did not increase tail bleeding. These data suggest that severe polymicrobial abdominal infection induces prothrombotic FXI activation, to the detriment of the host. Systemic anticoagulation by inhibiting FXI activation or FXIIa procoagulant activity during sepsis may therefore limit the development of disseminated intravascular coagulation without increasing bleeding risks.

AB - Severe bacterial sepsis often leads to a systemic procoagulant and proinflammatory condition that can manifest as disseminated intravascular coagulation, septic shock, and multiple organ failure. Because activation of the contact proteases factor XII (FXII), prekallikrein, and factor XI (FXI) can trigger coagulation and inflammatory responses, the contact factors have been considered potential targets for the treatment of sepsis. However, the pathogenic role of contact activation in severe infections has not been well defined. We therefore investigated whether an anticoagulant antibody (14E11) that selectively inhibits prothrombotic FXI activation by activated FXII (FXIIa) modifies the course of bowel perforation-induced peritoneal sepsis in mice. Early anticoagulation with 14E11 suppressed systemic thrombin- anti-thrombin complex formation, IL-6, and TNF-α levels, and reduced platelet consumption in the circulation and deposition in the blood vessels. Treatment with 14E11 within 12 hours after bowel perforation significantly improved survival compared with vehicle treatment, and the saturating dose did not increase tail bleeding. These data suggest that severe polymicrobial abdominal infection induces prothrombotic FXI activation, to the detriment of the host. Systemic anticoagulation by inhibiting FXI activation or FXIIa procoagulant activity during sepsis may therefore limit the development of disseminated intravascular coagulation without increasing bleeding risks.

UR - http://www.scopus.com/inward/record.url?scp=84861215870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861215870&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-10-386185

DO - 10.1182/blood-2011-10-386185

M3 - Article

C2 - 22442348

AN - SCOPUS:84861215870

VL - 119

SP - 4762

EP - 4768

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -